C4 Therapeutics, Inc.
CCCC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $11 | $6 | $7 | $5 |
| % Growth | 73.8% | -10.7% | 39.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $2 |
| Gross Profit | $11 | $6 | $7 | $3 |
| % Margin | 100% | 100% | 100% | 65.9% |
| R&D Expenses | $26 | $26 | $27 | $33 |
| G&A Expenses | $9 | $9 | $9 | $10 |
| SG&A Expenses | $9 | $9 | $9 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $11 | $0 | $0 | -$2 |
| Operating Expenses | $46 | $35 | $36 | $41 |
| Operating Income | -$34 | -$29 | -$29 | -$38 |
| % Margin | -306.4% | -441% | -402.9% | -728.4% |
| Other Income/Exp. Net | $2 | $2 | $3 | $3 |
| Pre-Tax Income | -$32 | -$26 | -$26 | -$34 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$32 | -$26 | -$26 | -$35 |
| % Margin | -286.4% | -402.6% | -363.7% | -667.8% |
| EPS | -0.44 | -0.37 | -0.37 | -0.49 |
| % Growth | -18.9% | 0% | 24.5% | – |
| EPS Diluted | -0.44 | -0.37 | -0.37 | -0.49 |
| Weighted Avg Shares Out | 73 | 71 | 71 | 71 |
| Weighted Avg Shares Out Dil | 73 | 71 | 71 | 71 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $3 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $0 | $2 |
| EBITDA | -$32 | -$28 | -$29 | -$33 |
| % Margin | -282.3% | -431.5% | -396.6% | -631.2% |